Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.
Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.
Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.
Inhibitor compounds developed by UC Irvine structural biologists and Northwestern University chemists have been shown to bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.
Research on an aerosol that jump-starts a rapid immune response to stifle viral respiratory infections before they can provoke asthma attacks has earned major funding from the National Institutes of Health.
A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).
PharmAthene, Inc. announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus – ACT international anthrax conference in Victoria, British Columbia, Canada.
PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
The chemical attacks in Syria could lower the bar for use of chemical weapons by terrorist organizations or rogue nations that could eventually pose a threat to the United States, says Alexander Garza, M.D., former assistant secretary of health affairs and chief medical officer at the U.S. Department of Homeland Security.
Researchers at the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, both part of the National Institutes of Health, have identified the cells in two distinct areas of the body that are simultaneously targeted for damage by anthrax toxins, eventually causing illness and sometimes death. Their findings, which appeared online today in Nature, are based on testing in mice.
A new hypothesis concerning a crucial step in the anthrax infection process has been advanced by scientists at the National Institute of Standards and Technology (NIST) and the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) at Fort Detrick, Md.
If terrorists targeted the United States with an anthrax attack, health care providers and policy makers would need key information - such as knowing the likelihood of an individual becoming infected, how many cases to expect and in what pattern, and how long to give antibiotics - to protect people from the deadly bacteria.
The Translational Genomics Research Institute (TGen) received another boost today for Science, Technology, Engineering and Math (STEM) education with a $20,000 grant from the Arizona Community Foundation (ACF).
Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.
A team led by William Fenical at Scripps Institution of Oceanography at UC San Diego has discovered a new chemical compound from an ocean microbe in a preliminary research finding that could one day set the stage for new treatments for anthrax and other ailments such as methicillin-resistant Staphylococcus aureus (MRSA).
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.
Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.